---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-23-000054"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:57:01.851994+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FDA approves Vertex's CASGEVY gene therapy for sickle cell disease at $2.2M list price

## Summary
- On Dec 8, 2023, FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.
- Wholesale acquisition cost (WAC) set at $2.2 million.
- CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy.

## SEC filing metadata
- accession: 0000875320-23-000054
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532023000054/0000875320-23-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532023000054/vrtx-20231208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-23-000054
- JSON: https://secwatch.observer/filing/0000875320-23-000054.json
- Plain text: https://secwatch.observer/filing/0000875320-23-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.